Pfizer Recalls Smoking Cessation Drug Chantix, Citing Presence of Possible Carcinogen




WASHINGTON, D.C. — Pfizer is recalling all lots of Chantix 0.5 mg and 1 mg. tablets due to the presence of a possible carcinogen, N-nitroso-varenicline, at or above acceptable limits, the Food and Drug Administration has announced.

In a Sept. 17 MedWatch alert, the agency explained that Pfizer has not received reports of adverse events related to the recall and that “the health benefits of stopping smoking outweigh the theoretical potential cancer risk from the nitrosamine impurity in varenicline.”

“Long-term ingestion of N-nitroso-varenicline may be associated with a theoretical potential increased cancer risk in humans, but there is no immediate …






UPCOMING CONFERENCES




HarrisMartin’s Webinar Series: MDL Update on Philips CPAP, BiPAP & Ventilator Litigation

October 21, 2021 - Haddonfield, NJ
HarrisMartin Webinar Series

MORE DETAILS



HarrisMartin's New Jersey Asbestos Litigation Conference

February 09, 2022 - New Brunswick, NJ
Hyatt Regency New Brunswick

MORE DETAILS